Literature DB >> 1453582

Early glycosylation products induce glomerular hyperfiltration in normal rats.

M Sabbatini1, G Sansone, F Uccello, A Giliberti, G Conte, V E Andreucci.   

Abstract

The effects of early glycosylation products (Amadori Products, AP) were investigated in male Munich-Wistar rats to establish whether AP play a role in the pathogenesis of glomerular hyperfiltration of early diabetic nephropathy. To mimic such a condition, normal rats were transfused with blood containing in vitro glycated serum (Group GLYC) to achieve plasma levels of Amadori products similar to those measured in rats with streptozotocin-induced diabetes. Rats transfused with normal blood were used as control (Group CON). Glomerular hemodynamics was evaluated in basal condition (B) and during acute hyperglycemia (HG). Blood transfusion did not alter basal hemodynamics. In Group CON, HG determined a rise of single nephron GFR (41.4 +/- 3.2 vs. 32.1 +/- 1.8 nl/min, P less than 0.005), secondary to the increase of afferent effective filtration pressure (EFPa, +19% vs. B, P less than 0.01). Rats of Group GLYC, in B, had values of SNGFR higher than those of Group CON B (46.8 +/- 3 nl/min, P less than 0.05, ANOVA). This increase was mediated by a significant reduction of glomerular afferent arteriole (Ra, -38% vs. Group CON B, P less than 0.05), a rise in hydrostatic gradient pressure in glomerular capillaries (delta P, +17%, P less than 0.05) and of EFPa (+31%, P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1453582     DOI: 10.1038/ki.1992.363

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

1.  Prevention of decline in renal function in the diabetic db/db mouse.

Authors:  M P Cohen; R S Clements; J A Cohen; C W Shearman
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

Review 2.  Molecular susceptibility to glycation and its implication in diabetes mellitus and related diseases.

Authors:  José D Méndez; Jianling Xie; Montserrat Aguilar-Hernández; Verna Méndez-Valenzuela
Journal:  Mol Cell Biochem       Date:  2010-07-31       Impact factor: 3.396

Review 3.  Glomerular hyperfiltration: definitions, mechanisms and clinical implications.

Authors:  Imed Helal; Godela M Fick-Brosnahan; Berenice Reed-Gitomer; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

4.  Effects of glycated albumin on mesangial cells: evidence for a role in diabetic nephropathy.

Authors:  F N Ziyadeh; M P Cohen
Journal:  Mol Cell Biochem       Date:  1993-08-11       Impact factor: 3.396

5.  Albumin modified by Amadori glucose adducts activates mesangial cell type IV collagen gene transcription.

Authors:  M P Cohen; E Hud; V Y Wu; F N Ziyadeh
Journal:  Mol Cell Biochem       Date:  1995-10-04       Impact factor: 3.396

Review 6.  New potential agents in treating diabetic kidney disease: the fourth act.

Authors:  Mark E Williams
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Combating diabetic nephropathy with drug therapy.

Authors:  D Martins; K Norris
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

8.  Role of aldose reductase in diabetes-induced retinal microglia activation.

Authors:  Kun-Che Chang; Biehuoy Shieh; J Mark Petrash
Journal:  Chem Biol Interact       Date:  2019-01-23       Impact factor: 5.192

Review 9.  Pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Radko Komers
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

10.  Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy.

Authors:  M P Cohen; K Sharma; Y Jin; E Hud; V Y Wu; J Tomaszewski; F N Ziyadeh
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.